Alexa Fluor 647-Labeled SLAMF7/CRACC/CD319 Fc Chimera: A "Multispectral Precision Probe" for Immunotherapy Targets

Alexa Fluor 647-Labeled SLAMF7/CRACC/CD319 Fc Chimera is a high-performance, modular detection probe designed for the key immunoregulatory receptor SLAMF7. As a self-ligand receptor primarily expressed on plasma cells, natural killer cells, cytotoxic T cells, and certain B cell subsets, signaling lymphocytic activation molecule family member 7 (SLAMF7) plays a central role in immune synapse formation, lymphocyte activation, and cytotoxic function regulation. It has garnered significant attention as a critical surface marker and therapeutic target for multiple myeloma. This probe combines the high-specificity recognition capability of SLAMF7's extracellular domain with the superior spectral properties of far-red fluorescent dye Alexa Fluor 647 and the universal functionality of Fc fragments, providing a high-resolution, highly compatible multispectral detection platform for immune cell analysis, hematologic malignancy diagnosis, and immunotherapy research.

This protein is a functionally engineered fusion probe constructed through genetic recombination and chemical modification, comprising three synergistic functional modules:

The core of the probe is the extracellular immunoglobulin-like domain of human SLAMF7 protein. SLAMF7 (also known as CRACC or CD319) belongs to the SLAM family of receptors, with its extracellular domain containing two immunoglobulin-like domains capable of mediating homotypic interactions. This module retains the ability to bind with cell surface native SLAMF7 receptors or soluble SLAMF7, enabling specific targeting of immune cells and tumor cells expressing this molecule.

The SLAMF7 extracellular domain is genetically fused with the Fc fragment of human immunoglobulin G to form a chimera. This design confers dual advantages:

Universal Detection and Signal Amplification Platform: The Fc fragment provides a universal binding site for any species-derived, any labeled form of anti-Fc secondary antibodies. Users can freely choose secondary antibodies with different fluorescent labels based on multicolor experiment channel allocation needs or convert signals to other detection modes.

Potential Functional Regulation Capability: Cross-linking of the probe on cell surfaces can be achieved through anti-Fc antibodies, mimicking the natural homodimerization of SLAMF7, potentially useful for studying the regulatory effects of receptor cross-linking on downstream signaling (e.g., EAT-2/SAP adaptor protein recruitment).

The high-performance fluorescent dye Alexa Fluor 647 is covalently linked to the protein. AF647 emits far-red fluorescence when excited by 633 nm or 640 nm lasers, with its core value lying in:

Exceptional Multicolor Compatibility: Its emission spectrum is highly separated from those of commonly used fluorophores like FITC, PE, and PerCP, minimizing spectral overlap (spillover) in multicolor flow cytometry or fluorescence imaging experiments, ensuring purity and quantitative accuracy of SLAMF7 signals.

High Brightness and Photostability: Brighter than traditional APC and more resistant to photobleaching, suitable for long-term live-cell imaging, high-content screening, and sensitive detection of weakly expressed antigens.

Ideal for Deep Tissue Imaging: Far-red light is less affected by tissue autofluorescence and has better penetration, facilitating high-quality imaging of tissue sections or 3D models.

This probe is a specialized solution for complex immunology multiparameter analysis. The SLAMF7 extracellular domain serves as an "intelligent homing device" that precisely recognizes target cells' "identity badges"; Alexa Fluor 647 acts as an "encrypted signal transmitter" operating on an independent, clear "far-red communication channel," ensuring interference-free information transmission in dense "spectral environments"; the Fc chimera is a "universal adapter" compatible with various "external devices" (different secondary antibodies), greatly expanding application scenarios.

The probe's core functionality lies in achieving high-specificity, high-resolution detection of SLAMF7 and studying its interactions.

Precise Labeling of SLAMF7-Positive Cells: The probe specifically binds to cells expressing SLAMF7, such as multiple myeloma cells, plasma cells, activated NK cells, and CD8+ T cell subsets. The high signal-to-noise ratio of AF647 enables clear distinction between positive and negative populations, even for cell subsets with low expression levels.

Cornerstone of Multicolor Flow Cytometry Analysis: In multicolor immunophenotyping, the cleanliness of the AF647 channel makes it an ideal choice. It can be easily combined with antibodies labeled in FITC, PE, BV421, etc., to simultaneously analyze co-expression of SLAMF7 with other surface markers (e.g., CD38, CD138, CD56, CD3, CD8), enabling fine subdivision of cell subsets.

Immunofluorescence and Confocal Imaging: Used to detect subcellular localization and expression patterns of SLAMF7 in cell smears, cell monolayers, or frozen tissue sections. Can study SLAMF7 aggregation at immune synapses or its distribution in tumor microenvironments.

Tissue Multiplex Labeling: In multiplex immunohistochemistry experiments, AF647-labeled probes are key components for constructing complex immune cell maps, enabling simultaneous observation of spatial relationships between SLAMF7+ cells and other immune or tumor cells.

Binding Kinetics Analysis: Using its Fc portion, the probe can be immobilized on biosensor chips for quantitative analysis of SLAMF7's interaction affinity and kinetics with itself or other proteins via surface plasmon resonance technology.

Competition and Blockade Experiments: As a soluble receptor, it can competitively inhibit SLAMF7 homotypic interactions between cells or block therapeutic antibodies (e.g., Elotuzumab) from binding to their targets, thereby validating the molecular basis of related functions.

This probe has broad applications in basic immunology, hematologic malignancy diagnosis/treatment, and immunotherapy development.

Tumor Cell Identification and Typing: SLAMF7 is highly expressed on most multiple myeloma cells, serving as a key differential marker distinguishing them from other B-cell malignancies (e.g., CLL, lymphoma) and reactive plasmacytosis. This probe is one of the core reagents for flow cytometry detection of minimal residual disease.

Studying SLAMF7's Pro-Tumor Functions: Investigating how SLAMF7 signaling promotes myeloma cell proliferation, survival, adhesion to bone marrow stromal cells, and drug resistance.

NK Cell Function Studies: SLAMF7 is an activating receptor on NK cells. This probe can be used to study dynamic SLAMF7 expression on NK cells in different activation states and its correlation with cytotoxic functions and cytokine production.

Plasma Cell and B Cell Subset Analysis: Used to identify and sort plasma cells at different differentiation stages and specific B cell subsets, studying their roles in autoimmune diseases and infections.

CD8+ T Cell Analysis: Detecting SLAMF7 expression on cytotoxic T cells to study its association with T cell exhaustion, memory differentiation, and antitumor functions.

Mechanistic Studies of Antibody Drugs Like Elotuzumab: Serving as a mimetic probe or competitor for Elotuzumab (an SLAMF7-targeting monoclonal antibody) to study how the drug enhances NK cell-mediated ADCC effects through SLAMF7 binding.

Target Validation: Before developing SLAMF7-targeted CAR therapies, accurately assessing SLAMF7 expression profiles on patient tumor cells and normal immune cells is crucial.

Treatment Monitoring and Escape Mechanisms: Post-treatment monitoring of SLAMF7 antigen expression changes is important for evaluating antigen escape under CAR-T cell pressure selection.

Combination Therapy Strategy Exploration: Investigating the impact of SLAMF7-targeting drugs on immune microenvironments when combined with immune checkpoint inhibitors or immunomodulators.

As an advanced tool, its development will be closely integrated with new paradigms in immunology research.

Mass Cytometry and Spectral Flow Cytometry: Developing metal-tagged antibodies or directly applicable spectral flow antibodies based on the same binding domain, enabling simultaneous, interference-free detection with 30-50 other parameters to deeply resolve the high heterogeneity of SLAMF7+ cells in tumors or tissues.

CITE-seq and Proteomics Integration: Combining with single-cell sequencing to correlate SLAMF7 protein expression with whole transcriptome information at single-cell resolution, precisely defining functional cell subsets.

Alexa Fluor 647-Labeled SLAMF7 Fc Chimera is a precision bridge connecting fundamental immunology discoveries with clinical immunotherapy translation. It transforms a receptor crucial for lymphocyte communication and tumor biology into a high-performance signal that can be clearly and independently interpreted in the most complex multicolor analysis systems. From deciphering molecular switches in NK cell killing to precise diagnosis and monitoring of multiple myeloma; from in-depth exploration of Elotuzumab's mechanisms to empowering the development and optimization of next-generation SLAMF7-CAR therapies, this "multispectral precision probe" remains an indispensable core tool for immunologists and oncologists. In the future, with advancements in single-cell spatial omics, live dynamic imaging, and AI analysis, high-performance protein tools like this probe will drive us toward systemic, dynamic, and quantitative new perspectives to more profoundly understand the mysteries of immune recognition and tumor immunoediting, accelerating the emergence of more effective and precise immunotherapy strategies.